Verteporfin (CL 318952)

For research use only. Not for use in humans.

製品コードS1786 別名:Visudyne

Verteporfin (CL 318952)化学構造

CAS No. 129497-78-5

Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 50500
JPY 55100
JPY 163000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(101)

製品安全説明書

VDA阻害剤の選択性比較

生物活性

製品説明 Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
ターゲット
VDA [1]
(Endothelial cells)
YAP/TEAD interaction [3]
()
体外試験

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. [1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL-60 NIfSd2hHfW6ldHnvckBie3OjeR?= MXn+NVAxKG6pL33M NUjSZ|l6TE2VTx?= Mn73bY5kemWjc3XzJGRPSSCocnHncYVvfGG2aX;uJIxmfmWucx?= M2m4OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNkC3O|ExLz5zME[wO|cyODxxYU6=
HL-60 M2jBfoN6fG:2b4jpZ4l1gSCjc4PhfS=> MnXJglExOCCwZz;tUC=> M3;yOWROW09? MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODZyN{exNEc,OTB4MEe3NVA9N2F-
Jurkat NX[2OXJISXCxcITvd4l{KGG|c3H5 MnXsglI5OCCwTR?= NF[0THpFVVOR MnqzbY5lfWOnczDhJGJkdC1{LXTldIVv\GWwdDDhdI9xfG:|aYO= NWnLXpNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGyOFU1OTVpPkGxNlQ2PDF3PD;hQi=>
RIF-1 M1;XPWZ2dmO2aX;uJIF{e2G7 MlfoNUDPxGdxbXy= NV7qWZdZTE2VTx?= M{LOW4Rm[3KnYYPld{BwgHmpZX6gZ49ve3WvcITpc44> NVLYTXpCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2NVU4OThpPkGyOlE2PzF6PD;hQi=>
RIF-1 MlezZ5l1d3SxeHnjbZR6KGG|c3H5 M1m4d|Eh|rypL33s MWTEUXNQ M17mZ4Rm[3KnYYPlJJRwKDJyINMxJFUmKGOnbHygd5Vzfmm4YXy= NYfaO|hHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2NVU4OThpPkGyOlE2PzF6PD;hQi=>
SVEC4-10 M370fmZ2dmO2aX;uJIF{e2G7 NYTGZpB[OjByIH7nM41t NX\lboFyTE2VTx?= NILIPJVqdmS3Y3XzJI1q[3KxdIXieYxmKGSncH;sfY1memm8YYTpc44> NF\JOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS2O|ExPid-MU[0OlcyODZ:L3G+
SVEC4-10 NVjreZVnTnWwY4Tpc44h[XO|YYm= M{L4RVIxOCCwZz;tcC=> M2[xPWROW09? NHXSdIZqdmS3Y3XzJJN1emW|czDhZ5RqdiCoaXLldkBnd3KvYYTpc44> M2OxZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NE[3NVA3Lz5zNkS2O|ExPjxxYU6=
ARPE-19 NWPVc3N7[3m2b4TvfIlkcXS7IHHzd4F6 NYDhcHd2hjBwMTFOwIcwdWx? MVPEUXNQ MoXQd4hwf3NiYTDkc5NmNWSncHXu[IVvfCC2b4jpZ4l1gQ>? MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7OEe5NFUoRjF4OUi3PVA2RC:jPh?=
ARPE-19 M4P4VmZ2dmO2aX;uJIF{e2G7 NVfWeJhKOC5yMTFOwIcwdWx? MWHEUXNQ NH\wV5lqdmO{ZXHz[ZMhXkWJRjDhcoQhemWmdXPld{BRTUSIIHX4dJJme3Orb36= MmHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7OEe5NFUoRjF4OUi3PVA2RC:jPh?=
Y-79 MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIHr[2t,OSEQvHevcYw> NFP3eJFFVVOR MWHk[YNz\WG|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w M3:xdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUe5O|Y1Lz5zOEW3PVc3PDxxYU6=
WERI-Rb1 NYHn[ZR7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1jLWp4yKM7:Zz;tcC=> M4fOXGROW09? NHj3dXll\WO{ZXHz[ZMhemW2aX7vZoxie3SxbXGgZ4VtdCCycn;sbYZmemG2aX;u MnTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3OlQoRjF6NUe5O|Y1RC:jPh?=
RB247C3 Mm\ES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUnod|ZFhjFizsznM41t MkPGSG1UVw>? MUPk[YNz\WG|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5OUe2OEc,OTh3N{m3OlQ9N2F-
RB355 NF\GSWFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MX3+NUDPxGdxbXy= MVnEUXNQ MYPk[YNz\WG|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w NW\sSXN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O|k4PjRpPkG4OVc6PzZ2PD;hQi=>
RB383 MonpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXTTUXAzhjFizsznM41t MVXEUXNQ MnX0[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= NVf0fodtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O|k4PjRpPkG4OVc6PzZ2PD;hQi=>
hFibro M4DQ[IN6fG:2b4jpZ4l1gSCjc4PhfS=> MoTONE42KML3Zz;tcC=> NUi4Z3o5TE2VTx?= NWLibHNj\GWlcnXhd4V{KH[rYXLpcIl1gSCkeTC4Okw2LQ>? MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2MUGxOEc,OjN2NEGxNVQ9N2F-
pTMC M4S0T4N6fG:2b4jpZ4l1gSCjc4PhfS=> M2\OUlAvPSEEtXevcYw> M1j0[WROW09? Mnn0[IVkemWjc3XzJJZq[WKrbHn0fUBjgSB7Mj65KS=> Mn:0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEGxNVQoRjJ|NESxNVE1RC:jPh?=
hTMC MlrJZ5l1d3SxeHnjbZR6KGG|c3H5 M{\QNVAvPSEEtXevcYw> NW\4[4E3TE2VTx?= MmXw[IVkemWjc3XzJJZq[WKrbHn0fUBjgSB6OD65KS=> Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEGxNVQoRjJ|NESxNVE1RC:jPh?=
ARPE-19 NFTDS5lkgXSxdH;4bYNqfHliYYPzZZk> NGftU3AxNjViwsXnM41t MmnzSG1UVw>? Mlvt[IVkemWjc3XzJJZq[WKrbHn0fUBjgSB3NT61KS=> M13kNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESxNVE1Lz5{M{S0NVEyPDxxYU6=
Panc-1 NFvwXYtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXHDO5lnOTBizszN MnnkSG1UVw>? M4DmWolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> MmHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmwOlkoRjJ2ME[5NFY6RC:jPh?=
MIA PaCa-2 M2\1d2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{n1dVExKM7:TR?= NVz6Wmt1TE2VTx?= NX\ETpZtcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NWLEcJJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlkxPjlpPkK0NFY6ODZ7PD;hQi=>
BxPC-3 MoT5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXHYRZFxOTBizszN NIDzemVFVVOR NIjNO2pqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgQ>? NFr3bJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
SU86.86 M1zhSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1jLdFExKM7:TR?= NUH0N4I3TE2VTx?= MWrpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfS=> M17lVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[5NFY6Lz5{NEC2PVA3QTxxYU6=
MCF-7 M{nzUGF2fG:yaHHnfUBie3OjeR?= M3qzbVExKM7:TR?= MoTESG1UVw>? NF75SpdqdmirYnn0d{Bo\W2laYThZolv\S2rbnT1Z4VlKGG3dH;wbIFogQ>? NFe1NpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
WERI NETqPYRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NFS5[Ih,OTBizsznM41t Mk\ZSG1UVw>? NG\KRXRqdmirYnn0d{Boem:5dHigc4YhemW2aX7vZoxie3SxbXGgZ4VtdHN? NX[wOnBXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|cyPDJpPkK0PFM4OTR{PD;hQi=>
WERI M13mWGZ2dmO2aX;uJIF{e2G7 NWLoSmpjhjFyIN88[{9udA>? MXzEUXNQ NHPrfohjdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdg>? NWC2eWhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|cyPDJpPkK0PFM4OTR{PD;hQi=>
Y-79 MWLGeY5kfGmxbjDhd5NigQ>? MV3+NVAh|rypL33s NG\MXZVFVVOR M4T1SoJtd2OtczDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9v NY\obpk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|cyPDJpPkK0PFM4OTR{PD;hQi=>
Y-79 NH;mNGJHfW6ldHnvckBie3OjeR?= M3\tTZ4yOCEQvHevcYw> M{XHT2ROW09? NGDqTXNi\m[nY4TzJHlCWC2WRVHEJJBzd3SxLX;uZ49o\W6nIIDheIh4[Xl? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|N{G0Nkc,OjR6M{exOFI9N2F-
Y-79 MWjGeY5kfGmxbjDhd5NigQ>? MVH+NVAh|rypL33s NGjB[2NFVVOR Mlrp[I94di2{ZXf1cIF1\XNicHz1dolxd3SnbnP5JI1iemuncjDPR3QuPA>? MorqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{exOFIoRjJ2OEO3NVQzRC:jPh?=
Phototoxicity assay M4Tn[2IyPkZzMB?= M3r3WFI1KGi{cx?= M2nIeGlEPTBiPTCxMlA4KM7:TR?= NWTxTWJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN|Y{QDlpPkK3NVM3Ozh7PD;hQi=>
Phototoxicity assay NHnSNW5DOT[IMUC= M32wRlI1KGi{cx?= NF30RVBKSzVyIE2gNU4zKM7:TR?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|NkO4PUc,OjdzM{[zPFk9N2F-
Phototoxicity assay NHvWbWNCOzd3 MUGyOEBpenN? NELl[oRKSzVyIE2gNk4xPiEQvF2= MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
Dark toxicity assay NXPoc4R7SjF4RkGw NF\IUXo1QCCqcoO= NGfnVJJKSzVyIE2gNlQvQTJizszN M1zscVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=
Dark toxicity assay Ml;RRlE3TjFy M1q3VlQ5KGi{cx?= NYXrRmpyUUN3MDC9JFI2NjB|IN88US=> M1KwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=
Dark toxicity assay M3PmbWE{PzV? NH;qOXo1QCCqcoO= MoXRTWM2OCB;IEO2MlM{KM7:TR?= NFnHZno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzOlM5QSd-MkexN|Y{QDl:L3G+
qHTS assay NEHZOVBVSzN{ NIn3O5FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay NXvGOXFOXS1{IF;T MlLGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?= NUO5UIl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay NUjQfVNxSTZ5Mx?= NHfUXG5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NF3abFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NE\1fIFFSU:\ MnfpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NV3sXJFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay MlK1V4Fwey1{ NXvOOJZjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> NFru[ZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay M1nyeGJVNTN5 Moq1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| M{jBO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NW\kVVZKWkR? Mn7ydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NVLTcVl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay NFG2UpZUUy2QLWPI MmXJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= MlT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NFP5dYNDXC1zMh?= MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? NFH6b2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NHfpcWNOTyB4MzCoOk1VTyCUKR?= MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? Mln0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MV3PTHMuPTB? MlPNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= Mn7WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NVvF[lVmWmh2MR?= MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NH7kRVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay MVXTTk1ISk1{ M3rjR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz MmnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay NG\GOJZUUy2QLV3D NYXwbWJpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NFHqUHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay M3zhe2xCVi13 NH3Y[4hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= NGLpeoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Antitumor assay NHPKbFNDOT[IMUC= M4HDSVIhdWdxa3e= MYOyJIhzew>? MXLBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDCNVZHOTBiY3XscJMhcW2ybHHueIVlKGmwIFO1O2JNNzZibX;1d4Uh[XO|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMjDt[{9s\yxiaY[gZYRucW6rc4TldoVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDpdpJi\GmjdHnvckB4cXSqIHzhd4VzKGG2IEG1NEBLN2OvJ{Kg[o9zKDFyIH3pcpM> M2XIdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
ECAD / Vimentin / Sox2 / CD44 / CD133; 

PubMed: 30467925     


Yes-associated protein 1 (YAP1), E-cadherin, vimentin (epithelial-mesenchymal transition [EMT] pathway), SOX2 CD44 and CD133 (autophagy markers) were detected by western blot in control, verteporfin (1 μmol/L) and verteporfin + 231-taxol (0.5 μmol/L) resistance groups.

c-Myc / Bcl-2; 

PubMed: 29416644     


In CAL27 cell lines, the expression of BCL-2 and C-MYC proteins decreased with the increase of Verteporfin concentration. The presented columns are given as the means ± SD. *p < 0.05, **P < 0.01, ***p < 0.001.

p-S6(S240/244) / p-4EBP1(S65); 

PubMed: 28202507     


KLE, EFE184 and NOU-1 were treated with Verteporfin (0.1 μM, 0.3 μM). After 36h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.

beta-catenin; 

PubMed: 28202507     


KLE, EFE184, NOU-1 and SKUT-2 were treated with 3 μM Verteporfin. After 24h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.

30467925 29416644 28202507
Growth inhibition assay
Cell viability; 

PubMed: 28042502     


A: Cell viability was determined by MTS assay after the UM cells were exposed to verteporfin for 72 hours. B: After treated with various concentrations of verteporfin for 24 hours, the UM cells (e.g., 92.1, Mel 270, Omm 1, Omm 2.3) were seeded in drug-free soft agar culture for 14 days. Colonies were counted. 

28042502
Immunofluorescence
p-YAP(Y357); 

PubMed: 28404908     


Confocal images of HEC-1-B cells and organoids which were subjected to immunofluorescence detection of A. YAP and B. phospho-YAP after VP treatment. YAP and phospho-YAP are conjugated with goat anti-mouse and goat anti-rabbit Alexa flour secondary antibodies respectively. (A) Upper panel bar=63x and lower panel bar = 20x. (B) Upper panel bar=63x and lower panel bar = 20x.

Calreticulin; 

PubMed: 30254296     


Calreticulin (CRT) significantly increased in VP-treated (5 µM, 2 h) U87 cells in both 21% and 1% O2 indicating likely ER stress.

YAP1; 

PubMed: 30254296     


Treatment of U343 cells with 5 μM VP between 1-8 h in both 21% and 1% O2 induced morphological changes. Scale bar represents 10 µm. VP: Verteporfin

28404908 30254296
体内試験 Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. [1]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (139.12 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 718.79
化学式

C41H42N4O8

CAS No. 129497-78-5
Storage 3 years-20°C powder
2 years-80°C in solvent (in the dark)
別名 Visudyne
Smiles COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C5N=C(C=C1[NH]2)C(=C5C)CCC(O)=O)C=C)C6=CC=C(C(C(=O)OC)C36C)C(=O)OC

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04590664 Recruiting Drug: Verteporfin Glioblastoma|Recurrent Glioblastoma Emory University|National Cancer Institute (NCI) January 15 2021 Phase 1|Phase 2
NCT03797547 Active not recruiting Other: AFLIBERCEPT Myopic Choroidal Neovascularisation Poitiers University Hospital June 22 2018 --
NCT01846273 Completed Drug: Ranibizumab|Drug: Verteporfin PDT|Drug: Sham PDT Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy Novartis Pharmaceuticals|Novartis August 7 2013 Phase 4
NCT00423189 Terminated Drug: Ranibizumab (Lucentis)|Drug: 0.5mg ranibizumab Age-Related Macular Degeneration David M. Brown M.D.|Novartis Pharmaceuticals|Greater Houston Retina Research January 2007 Phase 4
NCT00403442 Terminated Device: Verteporfin Therapy/ Drug: Bevacizumab Macular Degeneration Vitreous -Retina- Macula Consultants of New York|QLT Inc. September 2006 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

VDAシグナル伝達経路

相関VDA製品

Tags: Verteporfin (CL 318952)を買う | Verteporfin (CL 318952) ic50 | Verteporfin (CL 318952)供給者 | Verteporfin (CL 318952)を購入する | Verteporfin (CL 318952)費用 | Verteporfin (CL 318952)生産者 | オーダーVerteporfin (CL 318952) | Verteporfin (CL 318952)化学構造 | Verteporfin (CL 318952)分子量 | Verteporfin (CL 318952)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID